Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

Launched by CENTER FOR SIGHT LAS VEGAS · Jun 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether adding a medication called Rocklatan can further lower eye pressure in people with primary open-angle glaucoma who have already had a specific type of minimally invasive glaucoma surgery (called Hydrus microstent) along with cataract surgery. High eye pressure is a key concern in glaucoma, and lowering it helps protect vision. The study aims to see if Rocklatan can provide extra benefit in controlling eye pressure after this surgery.

Adults aged 40 and older with mild to moderate open-angle glaucoma who had cataract surgery and Hydrus microstent implantation between 3 months and 2 years ago may be eligible. Participants should have eye pressure within a certain range and either not be using glaucoma eye drops or be able to safely stop them before the study. People with severe glaucoma, other eye conditions, allergies to Rocklatan, or certain health issues would not qualify. If you join the study, you can expect close monitoring of your eye pressure and overall eye health to see how well Rocklatan works after surgery. This trial has not started recruiting yet, but it offers a chance to help researchers find better ways to manage glaucoma after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 40 years and older
• • Subjects who have mild to moderate Open Angle Glaucoma (OAG)
• • Subjects who have undergone uncomplicated cataract surgery and Hydrus microstent implantation \> 3 months prior to screening and within the last 2 years
• • Post-Hydrus subjects on 0-2 ocular hypotensive medication classes who can safely washout (if on ocular hypotensive medications)
• • Unmedicated or washed out IOP range between 16-26 mmHg
• Exclusion Criteria:
• • History of intraocular surgery except for uneventful refractive surgery or uncomplicated cataract surgery and hydrus microstent implantation
• • Prior Selective Laser Trabeculoplasty (SLT) within 18 months of surgery
• • Secondary glaucoma excluding pseudoexfoliation and pigmentary dispersion syndrome
• • Severe Open Angle Glaucoma
• • Narrow angles, other angle abnormalities or angle closure glaucoma
• • Allergy or intolerance to Rocklatan
• • History of corneal edema, or corneal disease or dystrophy
• • Current or history of intra-ocular infection or inflammation
• • History of retinal diseases that could affect diagnostic testing
• • Anticipated use of intra-ocular or topical steroids not associated with the study protocol
• • Pregnant, breastfeeding or planning to become pregnant during the study
• • Any condition in the opinion in the investigator that would potentially confound the results of the study